Active, not recruitingPhase 3NCT05946941
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
Studying Primary Sjögren disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Deucravacitinib(drug)
- Enrollment
- 774 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Local Institution - 0228, Fullerton, California, United States
- Local Institution - 0222, La Palma, California, United States
- Local Institution - 0218, San Francisco, California, United States
- Local Institution - 0203, Santa Monica, California, United States
- Local Institution - 0067, Denver, Colorado, United States
- Local Institution - 0049, Clearwater, Florida, United States
- Local Institution - 0226, Cooper City, Florida, United States
- Local Institution - 0223, Sarasota, Florida, United States
- Local Institution - 0140, Augusta, Georgia, United States
- Local Institution - 0229, Lawrenceville, Georgia, United States
- Local Institution - 0174, Skokie, Illinois, United States
- Local Institution - 0016, Kansas City, Kansas, United States
- Local Institution - 0017, Baton Rouge, Louisiana, United States
- Local Institution - 0125, Monroe, Louisiana, United States
- Local Institution - 0187, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05946941 on ClinicalTrials.govOther trials for Primary Sjögren disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07118241A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASELubris Bio Pty Ltd
- RECRUITINGNANCT07324733Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET ImagingPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGNANCT06877546Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's SyndromeKoite Health Oy
- ENROLLING BY INVITATIONNCT06879444"Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's"Pamukkale University
- RECRUITINGPHASE3NCT06684847A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndromeargenx
- RECRUITINGPHASE2NCT06440525A Study of RSLV-132 in Females With Sjögren's DiseaseResolve Therapeutics
- ENROLLING BY INVITATIONPHASE2NCT06519617Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular DamageQingwen Tao
- RECRUITINGNCT06528197Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western MedicineChina-Japan Friendship Hospital